Tempus AI (NASDAQ:TEM) Earns Outperform Rating from Analysts at William Blair

William Blair began coverage on shares of Tempus AI (NASDAQ:TEM) in a report issued on Tuesday morning, Marketbeat Ratings reports. The firm issued an outperform rating on the stock. William Blair also issued estimates for Tempus AI’s Q2 2024 earnings at ($3.22) EPS, Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.32) EPS, FY2024 earnings at ($4.35) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($1.33) EPS and FY2026 earnings at ($0.85) EPS.

A number of other brokerages have also recently weighed in on TEM. TD Cowen assumed coverage on Tempus AI in a research report on Tuesday. They set a buy rating and a $50.00 price target on the stock. Morgan Stanley initiated coverage on Tempus AI in a research report on Tuesday. They set an overweight rating and a $44.00 price target on the stock. Stifel Nicolaus initiated coverage on Tempus AI in a research report on Tuesday. They issued a buy rating and a $45.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on Tempus AI in a research report on Tuesday. They issued an overweight rating and a $42.00 target price on the stock. Finally, Loop Capital initiated coverage on Tempus AI in a research report on Tuesday. They issued a buy rating and a $48.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tempus AI presently has an average rating of Buy and an average target price of $45.63.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $39.76 on Tuesday. Tempus AI has a twelve month low of $22.89 and a twelve month high of $43.88.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.